Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Swanton

Showing results (131-140 of 439) with videos related to

Pageof 44
Sort By:
The Oncologist|October 25, 2011
Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancerHilda Wong, Roland Leung, Ava Kwong, et al.
European Urology|August 28, 2016
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven TherapeuticsChristopher E Barbieri, Arul M Chinnaiyan, Seth P Lerner, et al.
The Lancet. Oncology|August 14, 2018
Lung cancer in the UK: addressing geographical inequality and late diagnosisSara C Hiom, Harpal S Kumar, Charles Swanton, et al.
Annual Review of Genetics|October 9, 2014
Cancer: evolution within a lifetimeMarco Gerlinger, Nicholas McGranahan, Sally M Dewhurst, et al.
Open Biology|January 13, 2021
Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectoriesRobert E Hynds, Kristopher K Frese, David R Pearce, et al.
Molecular & Cellular Oncology|December 20, 2023
APOBEC3 as a driver of genetic intratumor heterogeneitySubramanian Venkatesan, Mihaela Angelova, Jirina Bartkova, et al.
Nature Reviews. Clinical Oncology|February 18, 2015
Can oncology recapitulate paleontology? Lessons from species extinctionsViola Walther, Crispin T Hiley, Darryl Shibata, et al.
Science Translational Medicine|April 17, 2015
Clonal status of actionable driver events and the timing of mutational processes in cancer evolutionNicholas McGranahan, Francesco Favero, Elza C de Bruin, et al.
Cancer Cell|April 29, 2022
The translational challenges of precision oncologyOriol Pich, Chris Bailey, Thomas B K Watkins, et al.
Journal of Cellular Biochemistry|July 29, 2010
Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancerRebecca A Burrell, Nicolai Juul, Stephen R Johnston, et al.
Pageof 44

Showing results (131-140 of 439) with videos related to

Sort By:
Pageof 44
The Oncologist|October 25, 2011
Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancerHilda Wong, Roland Leung, Ava Kwong, et al.
European Urology|August 28, 2016
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven TherapeuticsChristopher E Barbieri, Arul M Chinnaiyan, Seth P Lerner, et al.
The Lancet. Oncology|August 14, 2018
Lung cancer in the UK: addressing geographical inequality and late diagnosisSara C Hiom, Harpal S Kumar, Charles Swanton, et al.
Annual Review of Genetics|October 9, 2014
Cancer: evolution within a lifetimeMarco Gerlinger, Nicholas McGranahan, Sally M Dewhurst, et al.
Open Biology|January 13, 2021
Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectoriesRobert E Hynds, Kristopher K Frese, David R Pearce, et al.
Molecular & Cellular Oncology|December 20, 2023
APOBEC3 as a driver of genetic intratumor heterogeneitySubramanian Venkatesan, Mihaela Angelova, Jirina Bartkova, et al.
Nature Reviews. Clinical Oncology|February 18, 2015
Can oncology recapitulate paleontology? Lessons from species extinctionsViola Walther, Crispin T Hiley, Darryl Shibata, et al.
Science Translational Medicine|April 17, 2015
Clonal status of actionable driver events and the timing of mutational processes in cancer evolutionNicholas McGranahan, Francesco Favero, Elza C de Bruin, et al.
Cancer Cell|April 29, 2022
The translational challenges of precision oncologyOriol Pich, Chris Bailey, Thomas B K Watkins, et al.
Journal of Cellular Biochemistry|July 29, 2010
Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancerRebecca A Burrell, Nicolai Juul, Stephen R Johnston, et al.
Pageof 44